 |
 | |
 |  |
| We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level. |
NEUROCHEMICAL RESEARCH CORPORATION(NCRH) OVERVIEW AND EXECUTIVE SUMMARY INTRODUCTION We market and distribute cutting-edge, technologically advanced products while positioning our self as an innovative, aggressive leader in the emerging self-care industry, selling quality nutritional supplements, health and diet products and new-age cosmetics. We have identified potential markets for our product lines and will continue to create new market niches where there were none before, constantly generating new products that spin off the needs, hopes and desires of a newly emerging society. BUSINESS BACKGROUND The Food and Drug Administration (FDA) describes dietary supplements in its guide as “some of the hottest selling items on the market today and points to surveys showing that more than half of the U.S. adult population uses these products.” We envisioned and identified our market within this emerging consumer trend - a huge healthcare related shift - which is the public’s proactive stance in managing their own health needs in tandem with standard medical care. We were originally formed to market neuronutrient therapeutics for the treatment of substance abuse, including addiction to nicotine, alcohol and other drugs. Our therapies, known as QuitSystem®, have been successfully utilized in clinical and hospital protocols since 1992. Our products balance the supply of dopamine available to the brain. Cocaine, as well as most other chemical stimulants, deplete dopamine levels. Dopamine is responsible for the brain’s pleasure pathway that makes us feel good when we eat, socialize or procreate. Dopamine balancing is also responsible for assisting with a number of diseases, including Parkinson’s and male virility. PRODUCT BACKGROUND Our QuitSystem® neuronutrient therapeutics were originally developed by Dr. Forest Tennant in conjunction with LabCo Pharmaceuticals, Inc. These products positively affect the brain chemistry by increasing the levels of dopamine, “the pleasure pathway” in the brain’s reward system that is the basis of addiction. Dr. Tennant, Executive Director of Community Health Projects Group, a system of 26 dependency disorder and pain clinics and the largest in the Western United States, is an internationally recognized leader in the field of drug rehabilitation and sports medicine. OUR MARKET Catapulted by our successful history in the professional/clinical sector (Porter Memorial Hospital protocol - - Indiana & Haight Ashbury Clinics - - San Francisco) with our cutting edge dietary supplements, we are placing our products in mainstream distribution channels where pharmacies lead in the sales growth of dietary supplements. Our product mix was developed to meet the needs, hopes and desires of our newly emerging society, which includes some 80 million baby boomers firmly facing middle age and vigorously fighting the effects of aging and health. One contributing factor to the growth of supplements, for example, are those people being treated for depression with antidepressant drugs. At least one-third are dissatisfied with the results and 80% dislike the side effects and high cost. Through licensing arrangements with LabCo Pharmaceuticals, Inc., 12 to 20 Plus, Inc., H. Bana, Ltd., Overland Food Co. and our own research and development effort, our highly technical product portfolio includes the most advanced supplements on the market today. Our current products include QuitSystem® Recovery Management for prevention of relapse from drugs, alcohol and smoking; Anaplex™, the perfectly natural alternative to antidepressant drugs; VisionKare™, for eye health and counteracting the degenerative eye disorder, macular; Male Virility™, an alternative to Viagra; 12 to20 Plus™ cutting-edge acne therapies; Hinoki Bana™, an advanced patented treatment system for thinning hair and ChemoKare™, protecting healthy cells against chemotherapy damage and possible inhibition of carcinogenesis progression. We will carve our market niche by initiating a forceful public relations campaign stressing the highly technical nature and scientific evidence behind the ingredients via comprehensive newswire distribution to medical, healthcare and pharmaceutical editors at key television, print media and trade publications. We will implement a variety of marketing approaches via direct mail, trade and consumer broadcast and print advertising, all of which are designed to interface with an interactive Web site designed to bring buyers to our products via mass distribution channels. | ||||||||||||
|
| Home | Hot | SubjectMarks | PeopleMarks | Keepers | Settings |
| Terms Of Use | Contact Us | Copyright/IP Policy | Privacy Policy | About Us | FAQ | Advertise on SI |
| © 2026 Knight Sac Media. Data provided by Twelve Data, Alpha Vantage, and CityFALCON News |